Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lanraplenib - Kronos Bio

Drug Profile

Lanraplenib - Kronos Bio

Alternative Names: GS 9876; GS-SYK; GS-SYK-succinate; lanraplenib succinate

Latest Information Update: 20 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Developer Galapagos NV; Gilead Sciences; Kronos Bio
  • Class Amines; Anti-inflammatories; Antirheumatics; Imidazoles; Piperazines; Pyrazines; Small molecules
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute myeloid leukaemia

Highest Development Phases

  • Phase II Cutaneous lupus erythematosus; Lupus nephritis; Rheumatoid arthritis; Sjogren's syndrome
  • Discontinued Acute myeloid leukaemia

Most Recent Events

  • 18 Dec 2023 Lanraplenib - Kronos Bio is available for licensing as of 18 Dec 2023
  • 18 Dec 2023 Discontinued - Phase-I/II for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in Spain and USA (PO)
  • 18 Dec 2023 Adverse events and efficacy data from a phase-I/II trial in Acute myeloid leukaemia released by Kronos Bio
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top